Copyright
©The Author(s) 2023.
World J Clin Cases. Apr 16, 2023; 11(11): 2435-2442
Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2435
Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2435
Characteristics | Mean (min-max) | n(%) | |
Age | 22.8 (15-38) | 30 (100) | |
Sex | Male | 19 (63) | |
Female | 11 (37) | ||
Total | 30 (100) | ||
Total prescription days | 339.1 (230-1216) | ||
Total prescription dose (mg) | 4029.7 (230-10495) | ||
Daily prescription dose (mg/d) | 13.2 (8.01-20) | ||
Underlying disease | None | 23 (77) | |
Androgenetic alopecia | 1 (3) | ||
Asthma | 1 (3) | ||
Crohn’s disease | 1 (3) | ||
Ulcerative colitis | 1 (3) | ||
Seborrheic dermatitis | 1 (3) | ||
Urticaria | 2 (6) |
Laboratory | Month 1 (total number: 30), n (%) | Month 2 (total number: 26), n (%) | Month 3 (total number: 21), n (%) | Month 4 (total number: 20), n (%) | Month 5 (total number: 18), n (%) | Month 6 (total number: 13), n (%) |
AST | 2 (7) | 2 (8) | 4 (19) | 1 (5) | 0 (0) | 1 (8) |
ALT | 0 (0) | 1 (4) | 1 (5) | 1 (5) | 0 (0) | 1 (8) |
TG | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 0 (0) | 0 (0) |
HDL | 2 (7) | 2 (8) | 1 (5) | 0 (0) | 1 (6) | 0 (0) |
LDL | 21 (70) | 19 (73) | 14 (67) | 14 (70) | 11 (61) | 7 (54) |
Total cholesterol | 6 (20) | 4 (15) | 5 (24) | 3 (15) | 5 (28) | 3 (23) |
Blood test | Variable | 1-2 mo | 2-3 mo | 3-4 mo | 4-5 mo | 5-6 mo |
AST | Sex | 0.221 | 0.761 | 0.769 | 0.467 | 0.743 |
Prescription days | 0.721 | 0.341 | 0.584 | 0.777 | 0.020 | |
Prescription dose | 0.588 | 0.310 | 0.369 | 0.980 | 0.029 | |
Total | 0.523 | 0.434 | 0.868 | 0.311 | 0.153 | |
ALT | Sex | 0.296 | 0.362 | 0.174 | 0.912 | 0.927 |
Prescription days | 0.699 | 0.055 | 0.345 | 0.262 | 0.016 | |
Prescription dose | 0.948 | 0.081 | 0.527 | 0.314 | 0.021 | |
Total | 0.580 | 0.261 | 0.689 | 0.709 | 0.126 | |
TG | Sex | 0.818 | 0.357 | 0.538 | 0.858 | 0.313 |
Prescription days | 0.801 | 0.681 | 0.823 | 0.718 | 0.008 | |
Prescription dose | 0.730 | 0.355 | 0.876 | 0.883 | 0.009 | |
Total | 0.788 | 0.501 | 0.529 | 0.536 | 0.024 | |
HDL | Sex | 0.552 | 0.999 | 0.747 | 0.498 | 0.190 |
Prescription days | 0.475 | 0.227 | 0.579 | 0.922 | 0.323 | |
Prescription dose | 0.632 | 0.190 | 0.528 | 0.950 | 0.083 | |
Total | 0.521 | 0.232 | 0.716 | 0.611 | 0.018 | |
LDL | Sex | 0.464 | 0.524 | 0.510 | 0.715 | 0.445 |
Prescription days | 0.015 | 0.869 | 0.325 | 0.747 | 0.786 | |
Prescription dose | 0.006 | 0.918 | 0.167 | 0.842 | 0.835 | |
Total | 0.052 | 0.338 | 0.140 | 0.755 | 0.746 | |
Total cholesterol | Sex | 0.469 | 0.348 | 0.373 | 0.576 | 0.336 |
Prescription days | 0.066 | 0.761 | 0.310 | 0.869 | 0.761 | |
Prescription dose | 0.019 | 0.576 | 0.095 | 0.925 | 0.710 | |
Total | 0.104 | 0.228 | 0.076 | 0.698 | 0.427 |
- Citation: Park YJ, Shin HY, Choi WK, Lee AY, Lee SH, Hong JS. Optimal laboratory testing protocol for patients with acne taking oral isotretinoin. World J Clin Cases 2023; 11(11): 2435-2442
- URL: https://www.wjgnet.com/2307-8960/full/v11/i11/2435.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i11.2435